Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00456495 · ClinicalTrials.gov registry record · Phase 1
Effect of Ranibizumab on Malignant Conjunctival Neoplasia
A Phase 1 study of Conjunctival Neoplasms, sponsored by The New York Eye Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 5
- Enrollment target
- 1
- Study location
NCT00456495: Completed Phase 1 study of Conjunctival Neoplasms, sponsored by The New York Eye Cancer Center.
NCT00456495 is a Phase 1 study of Conjunctival Neoplasms that has completed, run by The New York Eye Cancer Center. The registered enrollment target is 5 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (92% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00456495, a Phase 1 study of Conjunctival Neoplasms, has completed, sponsored by The New York Eye Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 5 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to test the safety and tolerability of subconjunctival injection of ranibizumab in the treatment of malignant conjunctival neoplasia using the incidence and severity of adverse events. Our secondary objective is to assess the efficacy of ranibizumab treatment on malignant conjunctival neoplasia by evaluating tumor destruction or reduction as documented by slit-lamp photography and ultrasonographic imaging and the regression of blood vessels.
Primary Outcome
To test the safety and tolerability of subconjunctival injection of ranibizumab in the treatment of malignant conjunctival neoplasia - using comparative slit lamp examination \[anterior segment and ocular adnexal examination for adverse events (eg abrasion, melting), visual acuity (number of patients with decrease in visual acuity), and blood pressure at each visit (number of patients with increased blood pressure from baseline), and monthly urinalyis (number of patients with abnormal protein le
Conditions Studied
Interventions
- DRUG ranibizumab
Study Locations (1)
New York
- The New York Eye Cancer Center - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2007-03 |
| Est. Completion | 2010-09 |
| Phase | Phase 1 |
What the finished NCT00456495 record still lists
NCT00456495 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 5 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (92% lower).
The record links to 1 condition, with Conjunctival Neoplasms appearing as the primary indexed condition, and to 1 intervention - of which ranibizumab is the first listed.
NCT00456495 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT00456495 about?
NCT00456495 is a clinical study titled "Effect of Ranibizumab on Malignant Conjunctival Neoplasia". The purpose of this study is to test the safety and tolerability of subconjunctival injection of ranibizumab in the treatment of malignant conjunctival neoplasia using the incidence and severity of adverse events. Our secondary objective is to assess the efficacy of ranibizumab treatment on maligna...
What is the current status of trial NCT00456495?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 5 participants. The study started on 2007-03. Estimated completion is 2010-09.
What conditions does trial NCT00456495 study?
This clinical trial studies the following conditions: Conjunctival Neoplasms.
What interventions are being tested in trial NCT00456495?
The interventions under investigation include: ranibizumab (DRUG).
Who is sponsoring clinical trial NCT00456495?
This trial is sponsored by The New York Eye Cancer Center, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00456495 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00456495's enrollment target sits among peer trials
5 1989th of 2000 higher than 6 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia